1. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease;Aaron;Annals of Internal Medicine,2007
2. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD;Agustí;European Respiratory Journal,2014
3. GSK113107 A 12-week study to evaluate the 24 hour pulmonary function of fluticasone furoate (FF)/vilanterol inhalation powder (FF/VI inhalation powder) once daily compared with salmeterol/fluticasone propionate (FP) inhalation powder twice daily in subjects with chronic obstructive pulmonary disease (COPD) www.gsk-clinicalstudyregister.com/files2/gsk-113107-clinical-study-report-redact-v02.pdf
4. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes;Anzueto;COPD,2009
5. GSK100250 A randomized, double-blind, parallel group, 52-week study to compare the effect of fluticasone propionate/salmeterol Diskus combination product 250/50mcg bid with salmeterol diskus 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease www.gsk-clinicalstudyregister.com/files2/gsk-sco100250-clinical-study-report-redact.pdf